Compare AbbVie Inc (ABBV) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs JPMorgan Equity Premium Income ETF — how do they compare? AbbVie Inc trades at $248.46 (market cap $441.94B), while JPMorgan Equity Premium Income ETF trades at $57.86. The key difference: AbbVie Inc pays a 2.77% dividend while JPMorgan Equity Premium Income ETF pays none, and AbbVie Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | JEPI | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $59.88 |
52-Week Low | $197.38 | $55.29 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
JEPI trades at $57.86, up 0.37% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on generating income through covered calls, offering monthly dividends, though recent news highlights underperformance versus peers and tax inefficiencies. Key support and resistance cluster around $58.
Outlook is mixed: JEPI provides steady income attractive to retirees, but faces competition from higher-yielding alternatives and potential opportunity cost from capped upside. Risks include yield compression, tax treatment of distributions, and active management underperformance. Investors should weigh income needs against total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
